Share on StockTwits

Agenus (NASDAQ:AGEN) was downgraded by Zacks from an “outperform” rating to a “neutral” rating in a note issued to investors on Wednesday. They currently have a $4.20 price target on the stock. Zacks‘s price target would indicate a potential upside of 25.75% from the company’s current price.

Other equities research analysts have also recently issued reports about the stock. Analysts at HC Wainwright reiterated a “buy” rating on shares of Agenus in a research note on Tuesday, July 1st. Analysts at Maxim Group cut their price target on shares of Agenus from $17.00 to $11.00 in a research note on Thursday, May 8th. They now have a “buy” rating on the stock.

Agenus (NASDAQ:AGEN) traded down 1.76% during mid-day trading on Wednesday, hitting $3.34. The stock had a trading volume of 668,830 shares. Agenus has a 52-week low of $2.27 and a 52-week high of $5.27. The stock’s 50-day moving average is $3.24 and its 200-day moving average is $3.22. The company’s market cap is $207.9 million.

Agenus (NASDAQ:AGEN) last issued its quarterly earnings data on Thursday, May 8th. The company reported ($0.01) earnings per share for the quarter, beating the analysts’ consensus estimate of ($0.13) by $0.12. The company had revenue of $0.72 million for the quarter, compared to the consensus estimate of $0.55 million. On average, analysts predict that Agenus will post $-0.54 earnings per share for the current fiscal year.

Agenus Inc, including its subsidiaries, (NASDAQ:AGEN) is a biotechnology company focused on the development and commercialization of technologies to treat cancers and infectious diseases.

To view Zacks’ full report, visit Zacks’ official website.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.